Modes of Delivery Impact Maternal Oxidative Stress Biomarkers and Dynamic Thiol Disulphide Homeostasis
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Antalya, Turkey
- Alanya Training and Research Hospital Gynecology and Obstetrics Department
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
For VD group:
- Women with spontaneous uncomplicated vaginal delivery
- Women who were in the 38th week and vertex presentation and whose contractions had started naturally.
For CS group:
• Women in their 38th week of pregnancy who delivered by elective CS without uterine contractions
Exclusion Criteria:
- Participants who were smokers
- Participants who had a non-optimal pre-pregnancy body mass index
- Systemic diseases such as diabetes mellitus and gestational hypertension.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
vaginal delivery
35 women who had spontaneous vaginal deliveries
|
|
cesarean section
23 women who had elective cesarean sections without labor
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxidative stress markers
Time Frame: From January 2021 to August 2021
|
Total antioxidation state (μmol Trolox equivalent/ L),
|
From January 2021 to August 2021
|
|
Oxidative stress markers
Time Frame: From January 2021 to August 2021
|
Total oxidation status(μmol H2O2 equivalent/L)
|
From January 2021 to August 2021
|
|
Oxidative stress markers
Time Frame: From January 2021 to August 2021
|
Oxidative stress index (arbitrary unit)
|
From January 2021 to August 2021
|
|
Oxidative stress markers
Time Frame: From January 2021 to August 2021
|
Disulfide (-S-S-) (µmol / L) / alb (g / l)
|
From January 2021 to August 2021
|
|
Oxidative stress markers
Time Frame: From January 2021 to August 2021
|
Total thiol (µmol / L)
|
From January 2021 to August 2021
|
|
Oxidative stress markers
Time Frame: From January 2021 to August 2021
|
Native thiol (µmol / L) / alb (g / l)
|
From January 2021 to August 2021
|
|
Oxidative stress markers
Time Frame: From January 2021 to August 2021
|
Ischemia modified albumin (U/L)
|
From January 2021 to August 2021
|
|
Oxidative stress markers
Time Frame: From January 2021 to August 2021
|
Paroxanase (U/L)
|
From January 2021 to August 2021
|
|
Oxidative stress markers
Time Frame: From January 2021 to August 2021
|
Arylesterase (Ku/l)
|
From January 2021 to August 2021
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 18.09.2020 / 23-9
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.